Ileal Bile Acid Transporter Inhibitors in Cholestasis: Potential for More Than Just Paediatrics?
Liver International · 2026-03 · 46 (3)
DOI: 10.1111/liv.70524 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 06.02.2026. Verfasst von Mahesh Krishna und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Yale Liver Center, Yale University School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Cholestasis, Thiazepines, Organic Anion Transporters, Sodium-Dependent. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben.
Abstract (Originalsprache)
Ileal bile acid transporter inhibitors (IBATi) are a new, attractive therapeutic mechanism to alter the enterohepatic circulation through depletion of the bile acid pool by blocking bile acid reuptake in the ileum leading to improvements in pruritus and liver function in cholestatic liver diseases. These drugs may also have an impact on immunity, the gut microbiome, and motility. IBATi are approved in Japan for the treatment of idiopathic chronic constipation. There are two IBATi, maralixibat and odevixibat, that have been extensively investigated in clinical trials and are FDA approved for cholestatic pruritus in progressive familial intrahepatic cholestasis and Alagille syndrome. Clinical trials exploring IBATi in other cholestatic conditions, such as biliary atresia, primary biliary cholangitis, and primary sclerosing cholangitis, are currently ongoing. In this review, we will outline the emerging data regarding the physiology and mechanism of action for the IBATi class, an overview of clinical trials that led to the approval of maralixibat and odevixibat, ongoing clinical trials in adult cholestatic liver diseases, and the future of this drug class in systemic apical sodium bile acid transporter inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Yale Liver Center, Yale University School of Medicine, New Haven, Connecticut, USA.
ORCID-Profile: Mahesh Krishna, James Lorenzen Boyer
Zitieren
APA
Krishna, M., & Boyer, J. L. (2026). Ileal Bile Acid Transporter Inhibitors in Cholestasis: Potential for More Than Just Paediatrics?. Liver International, 46(3). https://doi.org/10.1111/liv.70524
Vancouver
Krishna M, Boyer JL. Ileal Bile Acid Transporter Inhibitors in Cholestasis: Potential for More Than Just Paediatrics?. Liver International. 2026;46(3). doi:10.1111/liv.70524
BibTeX
@article{Krishna2026,
author = {Krishna, Mahesh and Boyer, James Lorenzen},
title = {Ileal Bile Acid Transporter Inhibitors in Cholestasis: Potential for More Than Just Paediatrics?},
journal = {Liver International},
year = {2026},
volume = {46},
number = {3},
doi = {10.1111/liv.70524}
}
EUVIMED